innovation process of pharmaceuticals is a long, risky and very costly business, economists typically emphasise lack of profit … innovation process of drugs for children, and in improving the uncertain situation of pediatric therapy …

I analyze the effects of four types of medical innovation and cancer incidence on U.S. cancer mortality rates during … that there were no pre‐dated factors that drove both innovation and mortality and that there would have been parallel … trends in mortality in the absence of innovation, the estimates indicate that there were three major sources of the 13 …

downstream along innovation pathways. Importantly, interplay between IP and regulation creates feedback loops of cumulative … technological innovation. This Article highlights the functional relationships between IP and regulatory laws to advance a holistic … approach to medical innovation policy. It introduces the term “regulatory property” to describe how administrative oversight …

I analyze the effects of four types of medical innovation and cancer incidence on U.S. cancer mortality rates during …Under the assumption that there were no pre-dated factors that drove both innovation and mortality and that there would … have been parallel trends in mortality in the absence of innovation, the estimates indicate that there were three major …

As the innovation process of pharmaceuticals is a long, risky and very costly business, economists typically emphasise … in the analysis of the innovation process of drugs for children, and in improving the uncertain situation of pediatric …

.S. drug pricing system: Current law also provides weak incentives for medical innovation across wide areas, including vaccines … innovation not only slow the growth of U.S. life expectancy but also exacerbate racial disparities in health outcomes.High drug … prices and slow pharmaceutical progress are two facets of the same problem: a system that fails to reward medical innovation …